Insulin delivery devices market Size and Growth Rate – (2019 - 2024)
The insulin delivery devices market is expected to reach USD 17.27 billion by 2023 from USD 12.32 billion in 2018, growing at a CAGR of 6.99% during the forecast period 2018-2023.
Drivers
The growing rate of diabetes patients, rising exposure of population towards the diabetes risk factors, changes in lifestyle habits, and increasing demand for human insulin are driving the growth of the global insulin delivery devices market. In addition, availability of favorable medical reimbursements, increasing healthcare expenditure, rising advancements in human insulin delivery devices technologies, growing focus of market players on the development & commercialization of advanced human insulin delivery devices (such as pens & portable insulin pumps) are further fueling the growth of global insulin delivery devices market. However, stringent regulatory policies for product approval and requirement of high costs for product manufacturing are restraining the growth of the global insulin delivery devices market.
Opportunities
Insulin maintains sugar levels in the blood and essential for the people suffering from type I diabetes & type II diabetes. The development of insulin delivery devices has been encouraged in the past years. These devices are used to deliver insulin doses via parenteral route rather than the oral route of administration. Insulin delivery devices promote the absorption rate of insulin into the bloodstream from the site of injection to execute immediate pharmacological action of insulin. Some of the majorly used insulin delivery devices such as insulin syringes, insulin pens, insulin pen needles, insulin pumps, and insulin jet injectors.
Detailed Segmentation of the report:
Insulin delivery devices market -By Type:
Insulin delivery devices market -By Application:
Of these, insulin syringes commanded the largest share of the global insulin delivery devices market in 2018, whereas the insulin pens segment is estimated to grow at the highest CAGR during the forecast period 2018-2023.
Insulin delivery devices market -By Region:
North America accounted for the largest share of 40.5% of the global insulin delivery devices market in 2018, whereas Asia-Pacific is estimated to grow at the highest CAGR of 9.10% during the forecast period 2018-2023.
Companies leading the Global Insulin delivery devices market profiled in the report are
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Type
5.2.1 Introduction
5.2.2 Insulin Syringes
5.2.3 Insulin Pens
5.2.4 Insulin Pen Needles
5.2.5 Insulin Pumps
5.2.6 Insulin Jet Injectors
5.3 Application
5.3.1 Introduction
5.3.2 Type I Diabetes
5.3.3 Type II Diabetes
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle East
6.5.3 South Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Sanofi (France)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Eli Lilly and Company (U.S.)
8.4 Biocon Ltd. (India)
8.5 Julphar (U.A.E.)
8.6 Ypsomed AG (Switzerland)
8.7 Becton, Dickinson and Company (U.S.)
8.8 Wockhardt Ltd. (India)
8.9 B. Braun Meselgen AG (Switzerland)
8.10 Biodel Inc. (U.S.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
